Mogrify, a Cambridge, UK-based biopharmaceutical company advancing in vivo reprogramming therapies, raised additional $10M in Series A funding.
The round, which brought total amount to $46M in the round, was led by Astellas Venture Management and Parkwalk Advisors with participation from Ahren Innovation Capital, Trend Investment Group, and Dr Jonathan Milner, co-founder of Abcam Plc.
The company intends to use the funds for further advancement of its pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.
Led by CEO Dr. Darrin M. Disley, Mogrify leverages proprietary platform technologies that enable systematic identification of the key transcriptomic and epigenetic cell switches required to control human cell fate. The company’s pipeline aims to address degenerative diseases of the eye, ear and pancreas via direct in vivo restoration of clinically valuable cell types, and in doing so, transform the lives of patients suffering from vision loss, hearing loss and diabetes.
Proceeds from the financing will be used to advance Mogrify’s pipeline of in vivo reprogramming therapies, delivering the milestones necessary to facilitate a Series B fundraise in 2024/25 and subsequent progression of a lead program into first-in-human studies.
FinSMEs
02/10/2023